HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $60
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on BioXcel Therapeutics but lowers the price target from $66 to $60.
July 03, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioXcel Therapeutics' price target has been lowered from $66 to $60 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, but the maintained 'Buy' rating suggests that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100